Fig. 1: UCHL3 is overexpressed in GC and correlates with poor prognosis. | Cell Death & Disease

Fig. 1: UCHL3 is overexpressed in GC and correlates with poor prognosis.

From: UCHL3 depletion inhibits gastric cancer progression and enhances palbociclib sensitivity by regulating the AKT/CCND1 signaling axis via ENO1 ubiquitination

Fig. 1: UCHL3 is overexpressed in GC and correlates with poor prognosis.

A Exploration of gene mutations in deubiquitinating enzymes in gastric cancer (GC) using the cBioPortal website (https://www.cbioportal.org/, dataset: OncoSG, 2018), highlighting the top 15 genes with the highest amplification rates. B Intersection of significantly differentially expressed deubiquitinating enzyme genes in TCGA GC data with the top 15 genes exhibiting significant amplification mutations. C Differential expression of UCHL3 in GC tissues and adjacent tissues from the TCGA and GTEx databases using the GEPIA website (http://gepia.cancer-pku.cn/). D Analysis of UCHL3 expression in GEO datasets GSE184336, GSE27342, GSE29272, and GSE66229 (https://www.ncbi.nlm.nih.gov/geo/). E Representative IHC images of UCHL3 in GC tissues or adjacent tissues. F Survival analysis of the 127 GC patients based on IHC scores of UCHL3. G RT-qPCR analysis of UCHL3 expression in 20 pairs of GC tissues and matched adjacent normal tissues, presented as log2 (Tumor/Normal). H, I Representative Western blotting images and quantitative analysis of UCHL3 expression in GC cell lines and the gastric mucosal cell line GES-1 (H), and in eight pairs of GC tissues and matched adjacent normal tissues (I). Student’s t test: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Back to article page